European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies

CompletedOBSERVATIONAL
Enrollment

1,939

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

November 2, 2023

Study Completion Date

November 2, 2023

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Palbociclib + aromatase inhibitor

Palbociclib + an aromatase inhibitor therapy

DRUG

Aromatase inhibitor

Aromatase inhibitor monotherapy

Trial Locations (64)

3000

UZ Leuven, Leuven

3100

Universitaetsklinikum Sankt Poelten, Sankt Pölten

3500

Landesklinikum Krems, Krems

5280

Sankt Josef Hospital Braunau, Braunau am Inn

5404

Kantonsspital Baden AG, Baden

6130

Priv. Doz. OA Dr. Michael Hubalek, Schwaz

11510

Hospital Universitario de Puerto Real, Cadiz

13597

MediOnko-Institut GbR, Berlin

15706

Hospital Clínico de Santiago de Compostela, Santiago de Compostela

16816

Ruppiner Kliniken GmbH, Neuruppin

18014

Hospital Universitario Virgen de Las Nieves, Granada

18439

Gynäkologie Kompetenzzentrum Praxis Dr. med. Carsten Hielscher, Stralsund

24007

Complejo Asistencial Universitario de Leon, León

26655

Medizinische Studiengesellschaft NORD-WEST GmbH, Westerstede

26721

Studienzentrum UnterEms, Emden

28046

Hospital Universitario La Paz, Madrid

28222

Hospital Puerta de Hierro, Majadahonda

28223

Hospital Universitario Quiron Madrid, Pozuelo de Alarcón

30008

Hospital General Universitario Morales Meseguer, Murcia

31008

Complejo Hospitalario de Navarra, Pamplona

33098

St. Vincenz-Krankenhaus GmbH, Paderborn

36211

Complejo Hospitalario Universitario de Vigo. Area Sanitaria de Vigo. Hospital Alvaro Cunqueiro, Vigo, Pontevedra

39008

Hospital Universitario Marques de Valdecilla, Santander

41013

Hospital Universitario Virgen Del Rocio, Seville

43003

Hospital de Sant Pau i Santa Tecla, Tarragona

45147

Universitatsklinikum Essen, Essen

45600

Hospital nuestra señora del prado de Toledo, Talavera de La Reina, Toledo

46017

Hospital Universitario Dr. Peset, Valencia

46520

Hospital de Sagunto, Sagunto, Valencia

48013

Hospital Universitario de Basurto, Bilbao

48415

Überörtliche Gemeinschaftspraxis, Hamburg

50009

Hospital San Jorge Huesca, Zaragoza

55116

Institut für Versorgungsforschung GbR, Mainz

60389

Bethanien Center for Hematology and Oncology, Frankfurt

66123

Universität des Saarlandes, Saarbrücken

70286

Örebro University Hospital, Örebro

71065

Kreisklinikum Böblingen gGmbH, Frauenklinik Böblingen, Sindelfingen

97080

Universitätsklinikum Würzburg Frauenklinik und Poliklinik, Würzburg

D-31241

Frauenarztpraxis, Ilsede

04103

Universitätsklinikum Leipzig, Leipzig

01127

Group practice Goehler, Dresden

08908

Institut Catalâ Oncologia-L'Hospitalet, L'Hospitalet de Llobregat

02006

Complejo Universitario de Albacete, Albacete

631 88

Mälarsjukhuset, Eskilstuna

167 56

St Goran Hospital, Bromma

751 85

Uppsala University Hospital, Uppsala

Unknown

Kantonsspital Baselland, Liestal

HP7 0JD

Buckinghamshire Healthcare NHS Trust, Stoke Mandeville Hospital, Buckinghamshire

LL18 5UJ

Glan Clwyd Hospital, Rhyl

EH1 3EG

Western General Hospital, Waterloo Place

G12 0YH

Beatson West of Scotland Cancer Centre, Glasglow

LL57 2PW

Ysbyty Gwynedd Hospital, Bangor

PE30 4ET

Queen Elizabeth Hospital, Kings Lynn

TD6 9BS

Borders General Hospital, Roxburghshire

FK9 4SW

Forth Valley Royal Hospital, Stirling

SY3 8XQ

Shrewsbury and Telford Hospital NHS Trust, Shrewsbury

LL13 7TD

Wrexham Maelor Hospital, Wrexham

BD9 6RJ

Bradford Teaching Hospitals NHS Foundation Trust, Bradford

BD20 6TD

Airedale NHS Foundation Trust, Keighley

BA1 3NG

Royal United Hospital Bath NHS Trust, Bath

BB2 3HH

Royal Blackburn Hospital, Blackburn

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

TR1 3LJ

Royal Cornwall Hospital, Cornwall

GGS 1PB

Nottingham University Hospitals NHS Trust, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05043506 - European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies | Biotech Hunter | Biotech Hunter